

RECEIVED

MAR 18 2002

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No: 09/757,333
Filed: January 9, 2001
Applicant: Achilefu et al.
Title: **VERSATILE HYDROPHILIC DYES**
Art Unit: 1619
Examiner: Not yet assigned
Attorney Ref.: MRD-67

Cincinnati, Ohio 45202

U.S. Patent and Trademark Office
2011 South Clark Place
Customer Window, Box Sequence
Crystal Plaza Two, Lobby, Room 1B03
Arlington, Virginia 22202

Sir:

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR
PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE
AND/OR AMINO ACID SEQUENCE DISCLOSURES**


In response to your Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated February 19, 2002, please find enclosed a corrected computer diskette and paper copy, along with a copy of the CRF Problem Report which indicates that the corrected computer diskette forwarded to the United States Patent and Trademark Office on November 30, 2001 was damaged.

RECEIVED
MAR 13 2002
TECH CENTER 1600/2900
RECEIVED
MAR 12 2002
TECH CENTER 1600/2900
RECEIVED
MAR 12 2002
TECH CENTER 1600/2900
RECEIVED
APR 18 2002
TECH CENTER 1600/2900

No fee is believed indicated with this submission. However, should any fees be deemed necessary in conjunction with this request, the Examiner is authorized to charge those fees or credit any overpayment to Deposit Account 23-3000.

Respectfully submitted,

WOOD, HERRON & EVANS, L.L.P.



Beverly A. Lyman
Reg. No. 41,961

2700 Carew Tower
Cincinnati, Ohio 45202
Office: (513) 241-2324
Facsimile: (513) 421-7269
K:\MRD\67\Response to notice damaged diskette.wpd



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/757,333	01/09/2001	Samuel I. Achilefu	MRD-67

Beverly A. Lyman
Wood, Herron & Evans, L.L.P.
2700 Carew Tower
441 Vine Street
Cincinnati, OH 45202-2917

RECEIVED

MAR 18 2002

TECH CENTER 1600/2900

CONFIRMATION NO. 5506

FORMALITIES LETTER



OC000000007491063

Date Mailed: 02/19/2002

RECEIVED
TECH CENTER 1600/2900
02 MAR 2002
PM 2:25

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*


Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

CRF Problem Report

The Scientific and Technical Information Center (STIC) experienced a problem when processing the following computer readable form (CRF):

Application Serial Number: 09/757,333 B
Filing Date: 1/9/2001
Date Processed by STIC: 2/7/2002

RECEIVED

MAR 18 2002

STIC Contact: Mark Spencer, 703-308-4212

TECH CENTER 1600/2900

Nature of Problem:

The CRF (was):

- ☒ (circle one) Damaged or Unreadable (for Unreadable, see attached)
☐ Blank (no files on CRF) (see attached)
☐ Empty file (filename present, but no bytes in file) (see attached)
☐ Virus-infected. Virus name: _____ The STIC will not process the CRF.
☐ Not saved in ASCII text
☐ Sequence Listing was embedded in the file. According to Sequence Rules, submitted file should **only** be the Sequence Listing.
☐ Did not contain a Sequence Listing. (see attached sample)
☐ Other: _____

**PLEASE USE THE CHECKER VERSION 3.1 PROGRAM TO REDUCE ERRORS.
SEE BELOW FOR ADDRESS:**

<http://www.uspto.gov/web/offices/pac/checker>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail. Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom. Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<<http://www.uspto.gov/ebc/efs/downloads/documents.htm>> , EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
3. Hand Carry directly to:
U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7th Floor, Examiner Name, Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202
Or
U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202
4. Federal Express, United Parcel Service , or other delivery service to: U.S. Patent and Trademark Office, Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 01/29/2002

RECEIVED

MAR 18 2002

TECH CENTER 1600/2900

RECEIVED
TECH CENTER 1600/2900
02 MAR 12 PM 2:26

<110> Achilefu, Samuel I.
Rajagopalan, Raghavan
Dorshow, Richard B.
Bugaj, Joseph E.

Mallinckrodt Inc.

<120> Versatile Hydrophilic Dyes

<130> MRD-67

<140> US 09/757,333

<141> 2001-01-09

<150> US 09/484,321

<151> 2000-01-18

<160> 8

<170> Patent-In Version 3.1

<210> 1

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

MOD_RES

<221> (1)...(8)

<223> Xaa at location 1 represents D-Phe. Artificial sequence is completely synthesized.

<223> Xaa at locations 2 and 7 represents Cys with an intramolecular disulfide bond between two Cys amino acids. Artificial sequence is completely synthesized.

<223> Xaa at location 4 represents D-Trp. Artificial sequence is completely synthesized.

<400> 1

Xaa Xaa Tyr Xaa Lys Thr Xaa Thr
1 5

<210> 2

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

MOD_RES

<221> (1)...(8)

<223> Xaa at location 1 represents D-Phe. Artificial sequence is completely synthesized.

<223> Xaa at locations 2 and 7 represents Cys with an intramolecular disulfide bond between two Cys amino acids. Artificial sequence is completely synthesized.

<223> Xaa at location 4 represents D-Trp. Artificial sequence is completely synthesized.

<223> Xaa at location 8 represents Thr-OH. Artificial sequence is completely synthesized.

<400> 2

Xaa Xaa Tyr Xaa Lys Thr Xaa Xaa
1 5

<210>	3	
<211>	11	
<212>	PRT	
<213>	Peptide	
<400>	3	
Gly Ser Gly Gln Trp Ala Val Gly His Leu Met		
1	5	10

<210>	4	
<211>	11	
<212>	PRT	
<213>	Peptide	
<400>	4	
Gly Asp Gly Gln Trp Ala Val Gly His Leu Met		
1	5	10

<210>	5	
<211>	8	
<212>	PRT	
<213>	Peptide	
<400>	5	
Asp Tyr Met Gly Trp Met Asp Phe		
1	5	

<210>	6	
<211>	8	
<212>	PRT	
<213>	Artificial Sequence	
<220>		
<221>	MOD_RES	
<222>	(1)...(8)	
<223>	Xaa at locations 3 and 6 represents Norleucine.	
	Artificial sequence is completely synthesized.	
<400>	6	
Asp Tyr Xaa Gly Trp Xaa Asp Phe		
1	5	

<210> 7
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<221> MOD_RES
<222> (1)...(8)
<223> Xaa at location 1 represents D-Asp. Artificial sequence is completely synthesized.
<223> Xaa at locations 3 and 6 represents Norleucine. Artificial sequence is completely synthesized.

<400> 7
Xaa Tyr Xaa Gly Trp Xaa Asp Phe
1 5

<210> 8
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<221> MOD_RES
<222> (1)...(8)
<223> Xaa at location 1 represents D-Lys. Artificial sequence is completely synthesized.

<400> 8
Xaa Pro Arg Arg Pro Tyr Ile Leu
1 5